FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives
FDA approves Novartis’s Rhapsido for symptomatic dermographism, marking the first treatment for adults with friction-triggered chronic hives
Share
Why It Matters
Novartis got approval for a new medicine called Rhapsido. It treats a rare skin condition, which shows the company keeps creating helpful drugs.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.